RAPT
RAPT Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$58.01
+0.00%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-69.5%
Return on equity
-63.7%
Return on assets
-72.9%
Return on invested capital
0.00x
Asset turnover
-$86.6M
Cash from operations
$5.84
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2025